| Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer ML Telli, KM Timms, J Reid, B Hennessy, GB Mills, KC Jensen, Z Szallasi, ... Clinical cancer research 22 (15), 3764-3773, 2016 | 945 | 2016 |
| Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple … EA Mittendorf, H Zhang, CH Barrios, S Saji, KH Jung, R Hegg, A Koehler, ... The Lancet 396 (10257), 1090-1100, 2020 | 851 | 2020 |
| Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology WJ Gradishar, BO Anderson, J Abraham, R Aft, D Agnese, KH Allison, ... Journal of the National Comprehensive Cancer Network 18 (4), 452-478, 2020 | 808 | 2020 |
| Human induced pluripotent stem cell–derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity PW Burridge, YF Li, E Matsa, H Wu, SG Ong, A Sharma, A Holmström, ... Nature medicine 22 (5), 547-556, 2016 | 710 | 2016 |
| Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines AA Powell, AAH Talasaz, H Zhang, MA Coram, A Reddy, G Deng, ML Telli, ... PloS one 7 (5), e33788, 2012 | 647 | 2012 |
| Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology WJ Gradishar, MS Moran, J Abraham, R Aft, D Agnese, KH Allison, ... Journal of the National Comprehensive Cancer Network 20 (6), 691-722, 2022 | 593 | 2022 |
| Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally … D Miles, J Gligorov, F André, D Cameron, A Schneeweiss, C Barrios, B Xu, ... Annals of Oncology 32 (8), 994-1004, 2021 | 486 | 2021 |
| NCCN guidelines insights: breast cancer, version 1.2017 WJ Gradishar, BO Anderson, R Balassanian, SL Blair, HJ Burstein, A Cyr, ... Journal of the national comprehensive cancer network 15 (4), 433-451, 2017 | 476 | 2017 |
| Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility ML Telli, SA Hunt, RW Carlson, AE Guardino Journal of Clinical Oncology 25 (23), 3525-3533, 2007 | 463 | 2007 |
| Breast cancer, version 4.2017, NCCN clinical practice guidelines in oncology WJ Gradishar, BO Anderson, R Balassanian, SL Blair, HJ Burstein, A Cyr, ... Journal of the National Comprehensive Cancer Network 16 (3), 310-320, 2018 | 431 | 2018 |
| Invasive breast cancer version 1.2016, NCCN clinical practice guidelines in oncology WJ Gradishar, BO Anderson, R Balassanian, SL Blair, HJ Burstein, A Cyr, ... Journal of the National Comprehensive Cancer Network 14 (3), 324-354, 2016 | 373 | 2016 |
| Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer S Vinayak, SM Tolaney, L Schwartzberg, M Mita, G McCann, AR Tan, ... JAMA oncology 5 (8), 1132-1140, 2019 | 347 | 2019 |
| Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate ML Telli, RM Witteles, GA Fisher, S Srinivas Annals of oncology 19 (9), 1613-1618, 2008 | 285 | 2008 |
| NCCN guidelines® insights: Breast cancer, version 4.2021: Featured updates to the NCCN guidelines WJ Gradishar, MS Moran, J Abraham, R Aft, D Agnese, KH Allison, ... Journal of the National Comprehensive Cancer Network 19 (5), 484-493, 2021 | 268 | 2021 |
| Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation–Associated Breast Cancer With … ML Telli, KC Jensen, S Vinayak, AW Kurian, JA Lipson, PJ Flaherty, ... Journal of Clinical Oncology 33 (17), 1895-1901, 2015 | 259 | 2015 |
| Breast cancer version 2.2015 WJ Gradishar, BO Anderson, R Balassanian, SL Blair, HJ Burstein, A Cyr, ... Journal of the National Comprehensive Cancer Network 13 (4), 448-475, 2015 | 250 | 2015 |
| Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort S Masciari, DA Dillon, M Rath, M Robson, JN Weitzel, J Balmana, ... Breast cancer research and treatment 133, 1125-1130, 2012 | 238 | 2012 |
| Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ... Annals of oncology 33 (12), 1250-1268, 2022 | 220 | 2022 |
| Phyllodes tumors of the breast: natural history, diagnosis, and treatment ML Telli, KC Horst, AE Guardino, FM Dirbas, RW Carlson Journal of the National Comprehensive Cancer Network 5 (3), 324-330, 2007 | 212 | 2007 |
| NCCN guidelines insights: breast cancer, Version 3.2018: featured updates to the NCCN guidelines MP Goetz, WJ Gradishar, BO Anderson, J Abraham, R Aft, KH Allison, ... Journal of the National Comprehensive Cancer Network 17 (2), 118-126, 2019 | 204 | 2019 |
James FordStanfordVerified email at stanford.edu